文献速递胃肠外科围术期管理与 ERAS

新辅助化疗后腹腔镜与开腹全胃根治术治疗中上部胃癌的肿瘤学结局:真实世界研究

Oncological outcomes of laparoscopic versus open radical total gastrectomy for upper-middle gastric cancer after neoadjuvant chemotherapy: a study of real-world data.
PubMed 文献 · Surg Endosc · 2023-05-17

该回顾性研究分析了146例接受新辅助化疗(NAC)后行根治性全胃切除术的中上部胃癌患者,比较腹腔镜全胃切除术(LTG,89例)与开腹全胃切除术(OTG,57例)的长期结局。LTG组手术时间更短、术中出血更少、淋巴结清扫总数更多、化疗周期完成率更高,3年总生存(OS)显著优于OTG组;但经逆概率加权(IPW)校正后OS无显著差异。结论认为在有经验的中心,LTG可作为NAC后患者的首选,其长期生存不劣于OTG,且术中出血更少、化疗耐受性更好。

要点

  • LTG组手术时间更短(中位173 vs 215分钟,p<0.001),术中出血更少(62 vs 135 ml,p<0.001)。
  • LTG组淋巴结清扫总数更多(36 vs 31,p=0.043),化疗≥8周期完成率更高(37.1% vs 19.7%,p=0.027)。
  • LTG组3年OS显著更高(60.7% vs 35%,p=0.0013),但IPW校正后OS无显著差异(p=0.463)。

核心结论

  • 在有经验的胃癌手术中心,LTG可作为接受NAC后中上部胃癌患者的首选术式,其长期生存不劣于OTG,且术中出血更少、化疗耐受性更好。

主要发现

  • LTG组手术时间中位173分钟 vs OTG组215分钟(p<0.001),术中出血62 ml vs 135 ml(p<0.001)。
  • LTG组淋巴结清扫总数36枚 vs OTG组31枚(p=0.043),化疗≥8周期完成率37.1% vs 19.7%(p=0.027)。
  • LTG组3年OS为60.7%,OTG组为35%(p=0.0013);经IPW校正Lauren分型、ypTNM分期、NAC方案及手术时间后,两组OS无显著差异(p=0.463)。
  • 两组术后并发症发生率(25.8% vs 33.3%,p=0.215)和无复发生存(RFS)(p=0.561)相当。

临床怎么用

  • 对于接受NAC的中上部胃癌患者,在有经验的中心可优先考虑LTG,以降低术中出血并提高化疗完成率。
  • LTG的长期生存不劣于OTG,但需注意IPW校正后OS差异消失,提示生存获益可能受混杂因素影响。

局限性

  • 本研究为单中心回顾性分析,样本量有限(146例),可能存在选择偏倚和混杂因素。
  • IPW校正后OS无显著差异,提示LTG的生存优势可能并非独立于其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Laparoscopic technique has been increasingly used in gastrectomy, but the safety and feasibility of the laparoscopic total gastrectomy (LTG) for advanced proximal gastric cancer (PGC) after neoadjuvant chemotherapy (NAC) is unclear. METHODS: A retrospective analysis of 146 patients who received NAC followed by radical total gastrectomy at Fujian Medical University Union Hospital from January 2008 to December 2018 was performed. The primary endpoints were long-term outcomes. RESULTS: The patients were divided into two groups: 89 were in the LTG group and 57 were in the open total gastrectomy (OTG) group. The LTG group had a significantly shorter operative time (median 173 min vs. 215 min, p < 0.001), less intraoperative bleeding (62 ml vs. 135 ml, p < 0.001), higher total lymph node (LN) dissections (36 vs 31, p = 0.043), and higher total chemotherapy cycle completion rate (≥ 8 cycles) (37.1% vs. 19.7%, p = 0.027) than OTG. The 3-year overall survival (OS) of the LTG group was significantly higher than that of the OTG group (60.7% vs. 35%, p = 0.0013). Survival with inverse probability weighting(IPW) correction for Lauren type, ypTNM stage, NAC schemes and the times at which the surgery was performed showed that there was no significant difference in OS between the two groups (p = 0.463). Postoperative complications (25.8% vs. 33.3%, p = 0.215) and recurrence-free survival (RFS) (p = 0.561) between the LTG and OTG groups were also comparable. CONCLUSION: In experienced gastric cancer surgery centers, LTG is recommended as the preferred option for such patients who performed NAC, owing to its long-term survival is not inferior to OTG, and it offers less intraoperative bleeding, better chemotherapy tolerance than conventional open surgery.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Zheng HL, Shen LL, Xu BB, et al. Oncological outcomes of laparoscopic versus open radical total gastrectomy for upper-middle gastric cancer after neoadjuvant chemotherapy: a study of real-world data. Surg Endosc. 2023. PMID: 37198408. doi:10.1007/s00464-023-10084-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。